4 active not recruiting, 3 recruiting, 1 completed, 1 terminated. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Active not recruiting 4, Recruiting 3, Completed 1, Terminated 1 |
Follow Recurrent Oral Cavity Squamous Cell Carcinoma: new trials by email Literature Review of Recurrent Oral Cavity Squamous Cell Carcinoma trials Research Report on Recurrent Oral Cavity Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 44 | 2026-05-27 | 2026-10-26 |
| Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial Biospecimen Collection, Computed Tomography, Lovastatin - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Neck Squamous Cell Carcinoma of Unknown Primary | Phase 2 | Recruiting | Emory University | 28 | 2024-12-09 | 2026-02-11 |
| Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Biopsy Procedure, Biospecimen Collection, Computed Tomography - Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 52 | 2022-07-26 | 2026-09-21 |
| Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Carboplatin, Cemiplimab, Paclitaxel - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Marcelo Bonomi | 46 | 2021-11-30 | 2026-06-25 |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma Carboplatin, Cisplatin, Computed Tomography - Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 188 | 2021-04-27 | 2026-10-21 |
| Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Cabozantinib, Pembrolizumab - Metastatic Head and Neck Carcinoma, Paranasal Sinus Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Emory University | 36 | 2018-09-18 | 2026-01-23 |
| Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Capecitabine, Vorinostat - Paranasal Sinus Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 25 | 2010-12-01 | 2017-04-14 |
| Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Carboplatin, Cisplatin, Docetaxel - Metastatic Squamous Cell Carcinoma of the Hypopharynx, Metastatic Squamous Cell Carcinoma of the Larynx | Phase 2 | Completed | M.D. Anderson Cancer Center | 123 | 2010-02-05 | 2024-07-16 |
| Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Carboplatin, Paclitaxel, Sorafenib - Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma of the Hypopharynx | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 48 | 2007-04-25 | 2026-06-12 |
Squamous Cell Carcinoma of Head and Neck (9) · Laryngeal Neoplasms (4) · Mouth Neoplasms (4) · Carcinoma (3) · Hypopharyngeal Neoplasms (3) · Nasopharyngeal Carcinoma (2) · Oropharyngeal Neoplasms (2)
Carcinoma, Squamous Cell (9) · Head and Neck Neoplasms (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms by Site (9) · Neoplasms, Glandular and Epithelial (9) · Carcinoma (6) · Laryngeal Diseases (4) · Mouth Diseases (4) · Otorhinolaryngologic Diseases (4) · Otorhinolaryngologic Neoplasms (4) · Pharyngeal Diseases (4) · Pharyngeal Neoplasms (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4)
Carboplatin (4) · pembrolizumab (4) · Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Biopsy (2) · Cisplatin (2) · Paclitaxel (2) · Platinum (2) · Taxes (2) · cemiplimab (2) · Capecitabine (1) · Docetaxel (1) · Erlotinib Hydrochloride (1) · Lovastatin (1)
National Cancer Institute (NCI) (4) · Emory University (2) · M.D. Anderson Cancer Center (2) · Marcelo Bonomi (1)
United States (9) · Canada (1)
Dan P Zandberg (1) · Eric Chen (1) · George Blumenschein, MD (1) · Jacob S Thomas (1) · Marcelo R Bonomi, MD (1) · Matin Imanguli (1) · Nabil F. Saba, MD (1) · Nicole C Schmitt, D, FACS (1) · Xiuning Le (1)
P30CA138292 (2), N01CM00032 (1), N01CM00038 (1), U10CA180820 (1), UM1CA186691 (1), UM1CA186717 (1)